Resources: Affiliate News
Democrats Tout Federal Patent Take-Backs for Lowering Drug Costs
From the article: “March-in rights hasn’t been used before, so it’s hard to know what it would look like in practice,” said Rachel Sachs,…
The House Passed Its Prescription Drug Plan — Here’s What’s In It
From the article: Right now, drugmakers can raise the price of a drug as much as they want, whenever they want, as long as the market can bear it. Under…
First Opinion: Do large pharma companies provide drug development innovation?: Our analysis says no
From the article: Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug…
Harvard Law School researchers call for more regulation in medical AI
From the article: Existing safeguards from the FDA and other regulatory bodies will require significant updates in order to maintain safety and ethics in healthcare's use of constantly "…
Researchers call on regulators to reduce risks of AI in medicine
From the article: Continuous monitoring is critical if regulatory agencies such as the Food and Drug Administration are to reduce the risk in artificial and machine learning-based medical technology. That…
Inside Tennessee’s Final 1115 Medicaid Block Grant Proposal
From the article: The state’s response to comments in general seeks to provide general assurances that it intends to strengthen TennCare, not harm it. Perhaps most notable is…
Will sky-high drug prices spur the US to use an obscure power over patents?
From the article: The problem with appealing to march-in rights as a solution is the government has always refused to use the power it holds — as the Genzyme case…
White House report on Pelosi drug-pricing bill flawed, health policy experts say
From the article: Rachel Sachs, an associate professor of law at Washington University in St. Louis, noted that most of the economic logic the White House used would apply to…
Analysts Predict IPI and Senate Bill Unlikely to Impact Drug Industry Like Pelosi Bill
From the article: Rachel Sachs, associate professor of law at Washington University in St. Louis, told Focus that she agreed with the general findings of the report, adding: “In…
How a Democratic president could reduce drug prices without Congress
From the article: It has been sitting on the shelf for a long time for a reason. But the Yale authors make the case that there is strong precedent for…